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We describe a unique case of Granulocytic Sarcoma (GS) in a male, who presented to us with a painless right breast mass without
any prior history of Leukemia. GS is an extramedullary tumor of myeloproliferative precursors and may involve multiple sites of
the body, but involvement of male breast is extremely rare. In the absence of clinical history or hematological abnormality, GS
may be misdiagnosed, depending on the degree of myeloid diﬀerentiation present within the tumor. Often it is misdiagnosed as
lymphoma. Diagnosis is made by finding eosinophilic myelocytes, myeloperoxidase, chloroacetate esterase staining, and lysozyme
immunostain. Chemotherapy regimens similar to acute myeloid leukemia are recommended to treat GS. Recognition of this rare
entity is important because early, aggressive chemotherapy can induce regression of the tumor and improve patient longevity.
1. Introduction
Granulocytic sarcoma is a rare extramedullary tumor con-
sisting of primitive myeloid cells. It is also known as
chloroma, myeloblastoma, extramedullary leukemia, and
myeloid sarcoma. This localized growth of immature
myeloid precursors superficially resembles sarcoma. The
tumor is a solid collection of immature malignant white
blood cells (myoblasts) occurring outside the bone marrow,
and is a rare manifestation of acute and chronic leukemias. It
can occasionally precede the development of systemic disease
by weeks to years. GS was named as chloroma, because
of its greenish color. The histology of this unusual tumor was
first described by Burns in 1811 [1]. The term “chloroma,”
literally implying “green tumor”, was suggested by King in
1853 (Greek chloros, meaning green) [2]. The green colora-
tion is now known to be due to the presence and oxidation
of the myeloperoxidase enzyme. More than a century later,
in 1966, Rappaport coined the currently accepted term,
“granulocytic sarcoma,” recognizing the fact that the green
color is not universal [3].
These tumors may arise de novo, or could be associated
with other hematologic disorders such as acute myelogenous
leukemia, myelodysplastic syndrome, or with myeloprolifer-
ative disorders such as chronic myelogenous leukemia, poly-
cythemia vera, hypereosinophilia, and myeloid metaplasia.
GS can develop at any anatomic site and its distribution
commonly includes bone, nerve, lymph node, and skin, but
may involve a variety of soft tissues. In men, the breast has
been reported to be an uncommon site for granulocytic
sarcoma [4–6]. This extramedullary neoplasm may repre-
sent a diagnostic and therapeutic dilemma for both the
hematopathologist and oncologist.
2. A Case Report
A 56-year-old Caucasian male presented with right breast
enlargement of onemonth’s duration. It started with swelling
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Figure 1: Right breast mass with overlying skin discoloration.
Figure 2: CT chest showing eroding mass lesion.
under the right nipple that had progressed into a large mass.
Themass was painless but caused discomfort due to cosmetic
reasons. Over the past week the patient had also noticed a
change in skin color to orange and then to red, overlying
the lower outer quadrant of the right breast. The patient
denied any history of trauma, fever, weakness, recent weight
loss, or loss of appetite. He complained of mild left hip and
upper thigh pains of few days duration. His past medical
history was non-contributory. Family history was significant
for breast cancer in an older sister at age 55 years.
Physical examination revealed a 13 cm × 15 cm, well-
circumscribed, nontender mass, hard in consistency, and
fixed with the overlying skin and underlying structures
(Figure 1). The skin overlying the mass was pinkish. There
was no nipple retraction or discharge. The left breast struc-
tures were within normal limits. There was mild conjunctival
pallor, but no palpable axillary, inguinal, popliteal, or supra-
clavicular lymph nodes.
Laboratory studies showed hemoglobin of 9.6 g/dL
hematocrit of 28.7%, platelet count of 102 × k/µL and WBC
of 22 × k/µL with diﬀerential of 44% neutrophils, 30%
bands, 20% lymphocytes, 4% monocytes, and 2% eosino-
phils. CT scan of the chest revealed a large, 13 cm × 9 cm
mass involving the right anterior and lateral chest walls,
eroding into the thoracic cavity (Figure 2). The mass demon-
strated areas of low density suggestive of necrosis. The fifth
Figure 3: Trucut biopsy of the mass. Moderate-to-large size neo-
plastic cells with slightly irregular nuclei and conspicuous nucleoli.
Figure 4: Bone marrow biopsy showing hyperplastic marrow with
high M/E ratio.
and sixth right ribs had been eroded by the mass lesion. An
adjacent fluid collection was visible. There was no evidence
of lung involvement but a 1.5 cm right adrenal gland nodule
was noted. Bone scan performed with gamma camera
revealed a suspicious focus of increased uptake in the proxi-
mal left femoral shaft and small focus of increased uptake in
the superior occipital skull.
Trucut biopsy of the right breast mass showed myeloid
sarcoma (Figure 3). Bone marrow biopsy showed hyperplas-
tic marrow with high M/E ratio with shift to left (Figure 4).
Bone marrow immunohistochemical studies were positive
for lysozyme, myeloperoxidase, CD15, CD34, and CD43.
These findings were consistent with a Myeloid Neoplasm,
but not specific for a certain type. The diﬀerential diagnosis
proposed was chronic myeloid leukemia (CML), a myelodys-
plastic/myeloproliferative disease (e.g., chronic myelomono-
cytic leukemia, or CMML), and less likely, a myelodysplastic
syndrome. With pending chromosome analysis, patient was
started on therapeutic trial of Gleevec 600mg orally daily and
Allopurinol 300mg orally daily. Arrangements were made
for radiation therapy to the mass to improve local symptoms
and reduce the size of the tumor. Patient did well on this
therapy except for developing anemia for which he was
transfused.
Three days later, the patient sustained a fall resulting in an
acute transverse fracture of the proximal left femoral neck.
Left hip arthroplasty was performed. Bone reamings from
left femur, which were sent for studies, showed diﬀuse infil-
tration of neoplastic cells with extensive necrosis. Neoplastic
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cells were moderate to large in size and had modest to
moderate amount of pink cytoplasm and slightly irregular
nuclei with fine chromatin and conspicuous nucleoli. Mitotic
activities were frequently present, consistent with myeloid
neoplasm. The morphologic findings were suggestive of the
same neoplastic process as the previous bone marrow biopsy
and breast biopsy. Bonemarrow chromosome analysis report
came back as well and revealed complex clonal aberrations
including deletion of 5q, trisomy 8, and additional material
on the short arm of chromosome 17.
It was planned to start patient on AML-type chemother-
apy upon his recovery, but unfortunately, postoperatively
the patient developed respiratory failure and was transferred
to intensive care unit on assist control ventilation. He was
empirically started on Primaxin and Vancomycin for the pos-
sibility of healthcare associated pneumonia. Lovenox dose
was changed from prophylactic to therapeutic for possible
pulmonary embolism. CT angiogram of chest was obtained
which showed bilateral intraluminal filling defects in second
order branches consistent with pulmonary emboli. Multiple
attempts to wean him oﬀ the ventilator were unsuccessful.
Patient expired five days after surgery.
3. Discussion
Isolated granulocytic sarcomas are rare tumors associated
with myeloproliferative disorders or leukemias. They have
been reported both before and after the hematological diag-
nosis [4]. Usually, there is known bone marrow involvement
at the time of presentation and a clinical diagnosis is made.
Thus, presentation can occur either prior to or in association
with the underlying myeloid disorder or upon relapse.
This group of disorders can involve myeloblasts and neu-
trophil precursors, monoblasts, or can be a trilineagemyeloid
tumor of erythroid precursors, megakaryocytic precursors,
and granulocytic precursors [5]. It is frequently identified in
patients with chronic myeloid leukemia, myeloproliferative
disorders, or myelodysplasia, but most commonly these
tumors represent relapse or the initial presentation of acute
myeloid leukemia. Incidence is increased in FAB M4/M5
types, CD56 (+) blasts, cytogenetic abnormalities: t (8 : 21),
inversion 16, infant leukemia, 11q abnormalities, cellular
immune dysfunction, and with new treatments like allo-
geneic stem cell transplantation [5]. It has also been reported
as an isolated mass without prior history or subsequent
development of leukemia [5, 7].
Overall, GS has been classified into four categories: (a)
primary GS, (b) GS as a complication of acute myeloblastic
leukemia (AML), (c) GS as isolated recurrence of AML par-
ticularly during bone marrow remission and not followed by
medullary relapse, and (d) GS with concurrent bone marrow
relapse of AML [8]. Our patient belongs to category b,
GS as a complication of AML as per clinical history and lab
results.
GS is more common in males. Median age for males and
females is 32 and 34, respectively, andmost of the patients are
in the age range of 20–44 [9]. GS can present as a single lesion
or multiple lesions. Sizes can vary greatly and some are large
enough to cause compression symptoms or signs according
to their localization. GS is widespread and can involve almost
any part of the human body. Common sites of involvement
are lymph nodes 15%, skin 14%, head, and spinal cord 13%,
small intestine 11%, mediastinum 10%, bone 9%, ovary and
uterus 9%, and others 19% [9].
Breast involvement by GS is rare and that of the male is
extremely rare. Gynecomastia may be the first manifestation
of this disease or it may present as an isolated breast mass
[6, 10]. In the absence of clinical history or hematological
abnormality, granulocytic sarcoma may be misdiagnosed,
depending on the degree of myeloid diﬀerentiation present
within the tumor. A careful evaluation of the breast mass
is important, and GS should be diﬀerentiated from other
nonmammary malignancies of the breast; primary and sec-
ondary breast lymphoma, primary axillary nodal lymphoma,
metastatic acute lymphatic leukemia, metastatic plasma-
cytoma, primary angiosarcoma, metastatic rhabdomyosar-
coma, hematogenous metastasis from primary lung, ovarian,
cervical, thyroid and colonic carcinoma, malignant melano-
ma, carcinoma of the nasal cavity, and adenocarcinoma of
unknown primary [11].
3.1. Diagnosis. Mammographically, breast GS are noncalci-
fied irregular masses with poorly defined feathery margins
[11]. MRI will only show a mass lesion but is helpful in
evaluating response to treatment and detect the nonpalpable
relapse of the tumor [12].
GS infiltrates in tracts and tissue planes, usually preserv-
ing the tissue architecture without extensive tissue destruc-
tion and tumor necrosis. Histopathologically, these tumors
have been classified into well diﬀerentiated, poorly diﬀer-
entiated, and blastic types depending upon the level of
myeloid maturation by hematoxylin-eosin and PAS stained
sections [6, 13]. Histologic diagnosis remains diﬃcult. The
presence of eosinophilic myelocytes has traditionally been
one of the most reliable histologic findings in making a
diagnosis of GS. Tumors are considered well diﬀerentiated if
numerous eosinophilic myelocytes can be seen in any section
of a given case. Diagnosis can be confirmed with myelo-
peroxidase (MPO), chloroacetate esterase staining (leder
stain), and lysozyme immunostain(Ly). Histochemical stain-
ing to demonstrate the presence of MPO is the most
sensitive and specific antibody test for detection of myeloid
diﬀerentiation [14]. Electron microscopy, which reveals
azurophilic granules consistent with promyelocytes, helps
confirm diagnosis [7] but is rarely performed due to cost and
availability. Specific markers of cluster diﬀerentiation (CD)
typical of myeloid lineage can also be demonstrated. For
example, Chen and colleagues found that MPO was positive
in 97% of cases, Ly in 93%, CD34 in 47%, CD45 in 84%,
CD43 in 97%, CD68 in 93%, Bcl-2 in 68%, Tdt in 37%,
CD79a in 20%, CD20 in 10%, CD3 in 10%, and c-kit
(CD117) reactivity in 87% of the cases [15].
3.2. Diﬀerential Diagnosis. Diﬀerential diagnosis of GS on
fine needle aspiration (FNA) include large cell non-Hodgkin
lymphoma, lymphoblastic lymphoma, Hodgkin lymphoma,
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extramedullary hematopoiesis, poorly diﬀerentiated carci-
noma, infection, inflammation, plasmacytoma, and malig-
nant melanoma [13, 16].
In diﬀerential diagnosis, immunohistochemistry is the
most powerful tool and is regarded as essential for diagnosing
granulocytic myeloid tumor and distinguishing between its
various presentations.
3.3. Treatment. Treatment can be planned depending upon
the presentation, localization, and size of the tumor. There
is a significantly lower rate of progression to leukemia and
longer survival among patients who received any form of
chemotherapy at diagnosis of GS [17]. There is a general con-
sensus that all these patients must receive standard systemic
induction-intensification chemotherapy regimens similar to
those given in acute myeloid leukemia [5, 7, 18]. Surgical
excision and radiotherapy (tumor is highly radiosensitive)
can be curative, but mostly are performed to reduce the bulk
the of tumor and to relieve the compressive symptoms. High
dose methylprednisolone treatment has been reported to
markedly reduce the size of the tumor. Other adjuvant treat-
ment modalities that have been applied successfully include
low dose alpha-interferon and disodium pamidronate, low
dose methotrexate, allogeneic bone marrow transplant, and
autologous stem cell transplantation [5, 18].
Reports have emphasized the use of combined local and
systemic radical options, including chemotherapy, radiation
therapy, surgical intervention, and bone marrow transplan-
tation. Because of information on a limited number of
patients, there is no agreed upon optimal therapy. However,
systemic chemotherapy similar to that given for acute
myeloid leukemia with or without local radiotherapy may
result in long remissions [18, 19].
3.4. Prognosis. Generally, GS is associated with decreased
overall survival. Blastic types, age more than 50 years, and
extramedullary relapse following allogeneic bone marrow
transplant are significant adverse prognostic factors [5, 12,
19]. The median overall survival is about 20–22 months
[12, 13]. Themedian survival of patients with chromosome 8
abnormalities is 12 months [13]. In our patient, chro-
mosome analysis revealed complex clonal aberrations with
deletion of 5q. Deletion of 5q occurs in MDS/AML. In
the International Scoring System, MDS patients with this
karyotype pattern were placed in a poor prognostic category
[20].
4. Conclusion
GS is diﬃcult to recognize and may be easily overlooked or
misdiagnosed. GS may precede the diagnosis of a chronic
myeloproliferative disorder or acute myeloid leukemia, or
may present parallel to a hematologic diagnosis. An accurate
diagnosis of GS is of great clinical importance in the ongoing
management of hematologic malignancies. Precise diagnosis
is essential because all GS should be treated as acute myeloid
leukemias. Immunohistochemical and enzyme histochemi-
cal staining are useful in establishing the diagnosis, although
suspicion of the diagnosis on examination of routinely
stained sections is of paramount importance.
This case highlights a rare hematological cancer that
a clinician should consider when a patient presents with
a breast mass. Our objective of presenting this case is to
enhance awareness of GS in personnel providing health care.
Increased clinical awareness of this entity will facilitate early
diagnosis. A high index of suspicion is required and timely
recognition of GS is important, because aggressive induction
chemotherapy or radiation therapy can aﬀect outcome,
minimizing potentially preventable patient morbidity and
mortality.
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